| Title |
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
|
|---|---|
| Published in |
Breast Cancer Research, May 2012
|
| DOI | 10.1186/bcr3192 |
| Pubmed ID | |
| Authors |
Chandra R Tate, Lyndsay V Rhodes, H Chris Segar, Jennifer L Driver, F Nell Pounder, Matthew E Burow, Bridgette M Collins-Burow |
| Abstract |
Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies, younger age at onset, and early metastatic spread have contributed to the poor prognoses and outcomes associated with these malignancies. Here, we investigate the ability of the histone deacetylase inhibitor panobinostat (LBH589) to selectively target triple-negative breast cancer (TNBC) cell proliferation and survival in vitro and tumorigenesis in vivo. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Philippines | 1 | 25% |
| Latvia | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 260 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 1% |
| United Kingdom | 2 | <1% |
| Portugal | 1 | <1% |
| Indonesia | 1 | <1% |
| South Africa | 1 | <1% |
| Korea, Republic of | 1 | <1% |
| Egypt | 1 | <1% |
| Unknown | 250 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 57 | 22% |
| Student > Master | 38 | 15% |
| Researcher | 37 | 14% |
| Student > Bachelor | 30 | 12% |
| Student > Doctoral Student | 15 | 6% |
| Other | 44 | 17% |
| Unknown | 39 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 65 | 25% |
| Biochemistry, Genetics and Molecular Biology | 56 | 22% |
| Medicine and Dentistry | 39 | 15% |
| Chemistry | 19 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 4% |
| Other | 22 | 8% |
| Unknown | 48 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2019.
All research outputs
#6,510,425
of 26,017,215 outputs
Outputs from Breast Cancer Research
#746
of 2,086 outputs
Outputs of similar age
#42,791
of 179,439 outputs
Outputs of similar age from Breast Cancer Research
#11
of 36 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 2,086 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.3. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,439 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.